Course: Following a Moving Target: Current and Emerging Strategies for the Prevention and Management of COVID-19 in Patients with Multiple Sclerosis
Released: 0000-00-00
Program Description
Click to Go to the Event Registration
As our understanding of COVID-19 advances, so too does our understanding of its impact on multiple sclerosis (MS). Drs. Scott Newsome, Avindra Nath, and Gavin Giovannoni will help learners navigate the complexities of patient-specific factors (e.g., disability status, MS subtypes) and disease-modifying therapies (DMTs) to help improve both MS and COVID-related outcomes. Through in-depth discussion, the faculty will provide invaluable guidance on the optimal timing of DMT therapy post-vaccination while also equipping participants with practical strategies for prophylactic and outpatient COVID management in MS patients. This program explores real-world outcomes and emerging clinical trial data, enabling participants to assess the evolving landscape of COVID-19 care in the context of MS.
Agenda
MODULE 1:? The Immunology of COVID-19 and MS – Understanding Risks and Interactions
An update on COVID-19 immunology and its potential interplay with MS
Risk factors that may predict more severe COVID-19 in patients with MS
Potential impact of COVID-19 on MS symptom exacerbation
MODULE 2:? MS Treatment in the Modern Era
Risk for SARS-CoV-2 infections and/or severe outcomes with MS DMTs
Updated guidance for COVID-19 vaccinations
Safe relapse management with glucocorticoids
Shared-decision making strategies in the COVID-19 era
MODULE 3:? Prophylactic and Post-infection Management of COVID-19 in Immunocompromised Patients
Evidence with pre- and post-exposure prophylactic COVID-19 monoclonal antibodies (mAbs)
The evolving landscape of COVID-19 mAbs
Antiviral medications for confirmed SARS-CoV-2 infection
Intended Audience
This activity is intended for general neurologists, neurodegenerative disease specialists, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and long-term management of patients with MS.
Commercial Supporter
Supported by an educational grant from AstraZeneca.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
Identify clinical factors (e.g., disability status, MS subtypes) and DMTs (e.g., anti-CD20 therapy) that may influence risk for more severe or enduring symptoms of COVID-19 in patients with MS
Appraise clinical experience with and modern applicability of previous COVID-19 guidelines in with MS patients (e.g., vaccination requirements) and update care strategies in line with the current landscape
Evaluate real-world outcomes and emerging clinical trial data with pre- and post-exposure prophylactic treatments to prepare for their potential reprised role in minimizing COVID-19 risk in immunocompromised patients
Analyze the current evidence base regarding post-infection management of COVID-19 to maximize patient recovery
View Full Course